Details for New Drug Application (NDA): 019667

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

NDA 019667 describes SANDOSTATIN, which is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. Additional details are available on the SANDOSTATIN profile page.

The generic ingredient in SANDOSTATIN is octreotide acetate. There are twenty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

Summary for 019667

Tradename:	SANDOSTATIN
Applicant:	Novartis
Ingredient:	octreotide acetate
Patents:	0
Formulation / Manufacturing:	see details

Pharmacology for NDA: 019667

Mechanism of Action	Somatostatin Receptor Agonists

Medical Subject Heading (MeSH) Categories for 019667

Antineoplastic Agents, Hormonal
Gastrointestinal Agents

Suppliers and Packaging for NDA: 019667

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667	NDA	Novartis Pharmaceuticals Corporation	0078-0180	0078-0180-01	10 AMPULE in 1 PACKAGE (0078-0180-01) > 1 mL in 1 AMPULE (0078-0180-61)
SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667	NDA	Novartis Pharmaceuticals Corporation	0078-0181	0078-0181-01	10 AMPULE in 1 PACKAGE (0078-0181-01) > 1 mL in 1 AMPULE (0078-0181-61)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	EQ 0.05MG BASE/ML
Approval Date:	Oct 21, 1988	TE:	AP	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	EQ 0.1MG BASE/ML
Approval Date:	Oct 21, 1988	TE:	AP	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	EQ 0.5MG BASE/ML
Approval Date:	Oct 21, 1988	TE:	AP	RLD:	Yes

Expired US Patents for NDA 019667

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667-004	Jun 12, 1991	See Plans and Pricing	See Plans and Pricing
Novartis	SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667-001	Oct 21, 1988	See Plans and Pricing	See Plans and Pricing
Novartis	SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667-002	Oct 21, 1988	See Plans and Pricing	See Plans and Pricing
Novartis	SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667-002	Oct 21, 1988	See Plans and Pricing	See Plans and Pricing
Novartis	SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667-005	Jun 12, 1991	See Plans and Pricing	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.